Veeva Systems Inc
F:VEE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
V
|
Veeva Systems Inc
F:VEE
|
US |
|
Koninklijke Ahold Delhaize NV
OTC:AHODF
|
NL |
|
Zegona Communications PLC
F:1ZG
|
UK |
|
Cemex SAB de CV
NYSE:CX
|
MX |
|
Align Technology Inc
NASDAQ:ALGN
|
US |
|
K
|
Kuehne + Nagel International AG
OTC:KHNGF
|
CH |
|
Anheuser-Busch Inbev SA
XBRU:ABI
|
BE |
|
A
|
Altria Group Inc
SWB:PHM7
|
US |
|
E
|
Enel SpA
OTC:ENLAY
|
IT |
|
Koninklijke Ahold Delhaize NV
OTC:ADRNY
|
NL |
|
H
|
Heineken NV
OTC:HINKF
|
NL |
|
C
|
CCL Industries Inc
TSX:CCL.B
|
CA |
|
Resmed Inc
F:RMEA
|
US |
|
Orient Overseas (International) Ltd
HKEX:316
|
HK |
|
A
|
Allstate Corp
LSE:0HCZ
|
US |
|
C
|
Chipotle Mexican Grill Inc
SWB:C9F
|
US |
|
N
|
Nestle SA
XHAM:NESR
|
CH |
|
Formula One Group
NASDAQ:FWONA
|
US |
|
S
|
SSE PLC
SWB:SCT
|
UK |
Veeva Systems Inc
Veeva Systems makes cloud software for companies in pharmaceuticals, biotechnology, and medical devices. Its tools help customers manage drug sales, clinical trials, regulatory documents, quality records, and safety data. Instead of selling broad business software, Veeva focuses on the tightly regulated life sciences market, where companies need systems built around compliance and traceability. The company sells its products mainly as subscriptions, with some professional services to help customers set them up and connect them to existing systems. Its main customers are drug makers, biotech firms, and medtech companies, along with some partners in the wider life sciences supply chain. These customers use Veeva’s software to run key work processes across research, development, and commercial operations. What sets Veeva apart is its deep specialization. Life sciences companies face strict rules, long product cycles, and heavy documentation needs, so they often prefer software built specifically for that environment rather than generic enterprise tools. That makes Veeva an important software layer in the industry, sitting between the companies that develop medicines and the teams that bring those products to market.
Veeva Systems makes cloud software for companies in pharmaceuticals, biotechnology, and medical devices. Its tools help customers manage drug sales, clinical trials, regulatory documents, quality records, and safety data. Instead of selling broad business software, Veeva focuses on the tightly regulated life sciences market, where companies need systems built around compliance and traceability.
The company sells its products mainly as subscriptions, with some professional services to help customers set them up and connect them to existing systems. Its main customers are drug makers, biotech firms, and medtech companies, along with some partners in the wider life sciences supply chain. These customers use Veeva’s software to run key work processes across research, development, and commercial operations.
What sets Veeva apart is its deep specialization. Life sciences companies face strict rules, long product cycles, and heavy documentation needs, so they often prefer software built specifically for that environment rather than generic enterprise tools. That makes Veeva an important software layer in the industry, sitting between the companies that develop medicines and the teams that bring those products to market.
Strong quarter: Veeva reported $928 million of revenue and $416 million of operating income, with results ahead of guidance; management called it the company’s best CRM quarter ever.
Commercial momentum: Commercial subscription revenue grew about 13% year over year, including double-digit growth excluding Crossix, with strength across CRM, content, data and Crossix.
AI demand: Customer interest in Falcon is very high, driven by potential cost savings, compliance and efficiency benefits. Veeva said it is currently the rate limiter as it prepares the product and early-adopter deployments.
CRM wins: Veeva won three large CRM customers in the quarter, including two of the top 20 biopharma companies and Biogen. Management said only two top-20 decisions remain and expressed confidence in both.
Win-back opportunity: Some customers that selected Salesforce are reportedly experiencing project difficulties or delays. Veeva believes some could return, with the largest opportunity likely in 2027 and 2028.
New growth areas: Aspen is an early-stage CRM start-up within Veeva, while newer R&D products such as EDC, eCOA, RTSM, Safety and LIMS are expected to drive growth over the longer term.
Investment discipline: Management said Falcon and Aspen investments are included in updated FY 2027 guidance, with no material incremental investment expected this fiscal year; spending should scale with revenue.
Market backdrop: Life sciences customers appear to be continuing to invest despite geopolitical uncertainty, AI disruption and other policy changes, although a major interest-rate shift or escalation in conflict could affect the industry.
Management
Peter P. Gassner is a prominent figure in the technology and life sciences industries, best known as the co-founder and CEO of Veeva Systems Inc. Veeva Systems is a cloud-computing company focused on providing software solutions for the global life sciences industry. Under Gassner's leadership, the company has become a major player in the sector, known for its innovation and customer-centric approach. Gassner began his career in software development, working at IBM and later at Oracle, where he contributed significantly to the growth of their CRM division. His stint at Oracle honed his skills in enterprise software development and management, laying the groundwork for his future ventures. Before founding Veeva in 2007, Gassner also worked at Salesforce, where he was responsible for building the original technology team and was instrumental in developing the company’s platform. His strategic vision for Veeva Systems has always emphasized deep industry focus, product excellence, and customer success, which have been key factors in the company's expansion and efficacy. Under his guidance, Veeva has consistently grown its product offering, which includes applications for clinical trial management, regulatory compliance, quality management, and other areas critical to life sciences and pharmaceuticals. Peter Gassner's leadership style and business acumen have been widely recognized, earning him numerous accolades in the tech world. He is also known for advocating a genuine employee-centric culture and maintaining high standards of ethical business practices. Through his work with Veeva, Gassner has played a crucial role in transforming how pharmaceutical and biotech companies operate, ultimately aiming to improve patient outcomes globally.
Gassner began his career in software development, working at IBM and later at Oracle, where he contributed significantly to the growth of their CRM division. His stint at Oracle honed his skills in enterprise software development and management, laying the groundwork for his future ventures. Before founding Veeva in 2007, Gassner also worked at Salesforce, where he was responsible for building the original technology team and was instrumental in developing the company’s platform.
His strategic vision for Veeva Systems has always emphasized deep industry focus, product excellence, and customer success, which have been key factors in the company's expansion and efficacy. Under his guidance, Veeva has consistently grown its product offering, which includes applications for clinical trial management, regulatory compliance, quality management, and other areas critical to life sciences and pharmaceuticals.
Peter Gassner's leadership style and business acumen have been widely recognized, earning him numerous accolades in the tech world. He is also known for advocating a genuine employee-centric culture and maintaining high standards of ethical business practices.
Through his work with Veeva, Gassner has played a crucial role in transforming how pharmaceutical and biotech companies operate, ultimately aiming to improve patient outcomes globally.
Thomas D. Schwenger is a notable executive at Veeva Systems Inc., a cloud-computing company focused on the life sciences industry. As Chief Commercial Officer, he takes on the pivotal role of overseeing the company’s customer success and market expansion strategies. With a customer-centric approach, Schwenger is responsible for driving the company’s go-to-market functions including sales, services, and marketing. Before joining Veeva, Thomas Schwenger held several leadership roles that equipped him with extensive experience in managing large-scale operations and leading high-performance teams. He was previously affiliated with top-tier professional services firms, where he developed a strong foundation in strategic consulting and enterprise software solutions. Schwenger's educational background includes a focus on business and technology, which complements his professional experience in offering innovative solutions that align technology with business needs. His leadership at Veeva Systems is marked by a commitment to excellence and a drive to enhance the company’s value proposition to the life sciences sector. Through his strategic insights, Schwenger plays a crucial role in shaping the company's future trajectory and sustaining its competitive edge in the market.
Before joining Veeva, Thomas Schwenger held several leadership roles that equipped him with extensive experience in managing large-scale operations and leading high-performance teams. He was previously affiliated with top-tier professional services firms, where he developed a strong foundation in strategic consulting and enterprise software solutions.
Schwenger's educational background includes a focus on business and technology, which complements his professional experience in offering innovative solutions that align technology with business needs. His leadership at Veeva Systems is marked by a commitment to excellence and a drive to enhance the company’s value proposition to the life sciences sector. Through his strategic insights, Schwenger plays a crucial role in shaping the company's future trajectory and sustaining its competitive edge in the market.